In an attempt to develop effective and potentially safe anticancer agents, thirty-six 4-aminoquinoline derived sulfonyl analogs were designed and synthesized using a hybrid pharmacophore approach. The cytotoxicity of these compounds was determined using three breast tumor cell lines (MDA-MB231, MDA-MB468 and MCF7) and two matching non-cancer breast epithelial cell lines (184B5 and MCF10A). Although most of the compounds were quite effective on the breast cancer cells, the compound 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (13; VR23) emerged as potentially the most desirable one in this series of compounds. Data from the NCI-60 cancer panel screening show that compound 13 is effective on a wide range of different cancers. Importantly, compound 13 is needed up to 17.6-fold less doses to achieve the same IC 50 against cancer than non-cancer cells (MDA-MB468 vs MCF10A), suggesting that it can potentially be less toxic to normal cells. Cancer cells formed multiple centrosomes in the presence of compound 13, resulting in the cell cycle arrest at prometa-meta phase. This abnormality leads to eventual cell demise with sub-G1 DNA content typically shown with apoptotic cells. In addition, compound 13 also causes an increase in lysosomal volume in cancer but not in noncancer cells, which may contribute at least in part to its preferential cancer cell-killing. The cancer cell-killing effect of compound 13 is highly potentiated when combined with either bortezomib or monastrol.
growth/proliferation after 48 h incubation in the presence of a compound (examples shown in Supplementary  Fig. S1 ). Table 1 shows the GI 50 values (μM), the concentration of each compound required to inhibit the growth of each cell line by 50%. The data for CQ and cisplatin were included as references. The antigrowth activity of 4-piperazinylquinoline derived sulfonyl compounds against the three breast cancer cell lines (MDA-MB231, MDA-MB468, and MCF7) revealed that most of the compounds possess growth inhibitory property at the micromolar range to reach GI 50 values. The differences in the GI 50 values may be attributable to such factors as the nature of the sulfonyl group and the halogen substitution on the 7 th position of the 4-piperazinylquinoline ring system, and the genetic and biochemical background of the cell lines.
The structure-activity relationship (SAR) analysis suggests that the compounds derived from the 7-chloro-4-piperazinylquinoline ring system (except compounds 11, 12, 14 and 15) show generally better antigrowth activity on breast cancer cells than those derived from bioisoteric replacement of 7-chloro group with 50 values, determined at 48 h post-treatment, were calculated from sigmoidal dose response curves (variable slope), which were generated with GraphPad Prism V. 4.02. c Values are mean of triplicates of at least two independent experiments. 7-trifluoromethyl substitution on the 4-aminoquinoline ring system ( Table 1 ). The antigrowth effects generally increase in the following order: MCF7 > MDA-MB468 > MDA-MB231 cancer cells.
The introduction of a methyl group on sulfonyl analogs (compounds 7 and 16) shows less antigrowth effects, suggesting that methyl substitution is not favorable for the anticancer activity of sulfonyl analogs regardless the presence of a -Cl or -CF 3 group at the 7 th position. In contrast, the introduction of the liphophilic tosyl group substitution (compounds 8 and 17) on sulfonyl analogs resulted in a substantial increase in the antigrowth activity on MDA-MB231, MDA-MB468 and MCF7 cells. In addition, the introduction of a bulky liphophilic biphenyl group on sulfonyl analogs (compounds 9 and 18) showed an increase in antigrowth activity on all three breast cancer cell lines. These data clearly suggest that bulky lipophilic substitutions are advantageous for the increase in the antigrowth activity on these cancer cell lines.
The 4-chloro phenyl substituted hybrid compound 10 shows an increase in antigrowth activity by 3-fold on MCF7 in comparison to the methyl substituted compound 7. Furthermore, the introduction of 2,4-dichloro phenyl substitution (11) shows a decrease in antigrowth activity on all cell lines examined. However, this is completely opposite in compounds derived from the 7-trifluoro-4-piperazinylquinoline ring system, in that 2,4-dichloro phenyl substituted hybrid compound (20) shows an increase in antigrowth activity by 2-fold on MDA-MB231 in comparison to the methyl substituted compound (16) . Furthermore, the introduction of 4-chloro phenyl substitution (10) shows a decrease in antigrowth activity on all three cell lines examined.
The introduction of 3-nitro phenyl substitution (compounds 12 and 21) was generally not effective. The 2,4-dinitro phenyl substitution (13 and 22) shows an increase in potency by 1.1-12.47-fold on MCF7 cells, compared to mono nitro substituted compounds (12 and 21) . In this case, a -Cl group at the 7 th position (compound 13) appears to be more favorable than a -CF 3 group (compound 22), since the former shows higher antigrowth effects on cancer cells than non-cancer cells. These results suggest that the disubstituted electron withdrawing groups in the phenyl ring system are generally more favorable for anticancer activity.
The introduction of N,N-dimethylnaphthalenyl (compounds 14 and 23) and thiophenyl-2-carboxylic acid methyl ester substitutions (compounds 15 and 24) on sulfonyl analogs are less potent, suggesting that these modifications are not favorable for anticancer activity of sulfonyl analogs, regardless the presence of a -Cl or a -CF 3 group at the 7 th position. SAR analysis suggests that the compounds derived from the 1,3-diamino propane-linked 7-chloro-4-amino quinoline ring system (except compound 28 and 30) show generally better antigrowth activity on breast cancer cells than those derived from bioisoteric replacement of a 7-chloro group with a 7-trifluoromethyl substitution on the 4-aminoquinoline ring system ( Table 1) . The introduction of a methyl group on sulfonamide analogs (compounds 25 and 34) is less potent, suggesting that a methyl substitution is not favorable for the anticancer activity of sulfonamide analogs, regardless the presence of a -Cl or a -CF 3 group at the 7 th position. In contrast, the introduction of the tosyl group substitution (compounds 26 and 35) on sulfonamide analogs resulted in a substantial increase in potency on MDA-MB231, MDA-MB468 and MCF7 cells. The introduction of a bulky biphenyl group (compounds 27 and 36) on sulfonamide analogs also shows an increase in potency on all three cancer cell lines. These data clearly suggest that lipophilic and bulky substitutions are advantageous for the increase in potency against cancer cells.
Two 4-chloro phenyl substituted hybrid compounds (28 and 37) show increases in potency by 3.5-4.4-fold on MDA-MB231 in comparison to methyl substituted compounds (25 and 34). Furthermore, the introduction of 2,4-dichloro phenyl substitution (compounds 29 and 38) shows increases in potency on all three cancer cell lines examined, which are generally more effective than 4-chloro phenyl substituted compounds (28 and 37). The introduction of a 3-nitro phenyl substitution (compounds 30 and 39) is generally not very effective. The 2,4-dinitro phenyl substitution (31 and 40) shows an increase in antigrowth activity by 1.7-2.3-fold against MDA-MB231, compared to mono nitro substituted compounds (30 and 39). In this case, a -CF 3 group at the 7 th position (compound 20) appears to be more favorable than a -Cl group (compound 31), since the former shows higher antigrowth effects on cancer than non-cancer cells. These results suggest that the disubstituted electron withdrawing groups in the phenyl ring system are generally more favorable for anticancer activity.
The introduction of the N,N-dimethylnaphthalenyl substitution on the 7-chloro-4-aminoquinoline sulfonamide compound (32) led to a 15.7-fold increase in potency against MCF7 (GI 50 = 2.45 µM), compared to CQ (GI 50 = 38.44 µM). However, this modification results in the loss of preferential antigrowth effects on cancer cells, as they also show effective antigrowth effects on non-cancer cells. The compounds derived from the thiophenyl-2-carboxylic acid methyl ester substitution on the 7-chloro (33) and 7-trifluoromethyl (42) 7, 8, 17 . Overall, it is quite clear that a piperazinyl linker is favorable for the increase in anticancer activity, probably due to their rigid nature.
Many sulfonyl compounds show selective cytotoxicity on cancer over normal cells. This selectivity is likely the result of the heterocyclic attachment to the sulfonyl pharmacophore 17, 20, 24 . In the present study sulfonyl and sulfonamide groups are linked with "Sui-generic" pharmacophore of 4-aminoquinoline, therefore some of compounds Fig. 3 .
Among this series the compound 13 (a.k.a.VR23
25
) is particularly effective on cancer cells, as its GI 50 values are 3.4 ± 0.1, 0.7 ± 0.1 and 2.3 ± 0.1 µM on MDA-MB231, MDA-MB468 and MCF7 cells, respectively (Table 1) . These data from SRB were further confirmed by clonogenic assay, as examples are shown in Supplementary Fig. S1 . Our data demonstrate that the antigrowth effects of compound 13 against cancer cell lines are 4.1-to 16.6-fold more effective than the parental CQ (Table 1 ). Compound 13 is also 4.3-fold (MDA-MB231), 9.2-fold (MDA-MB468), and 11.1-fold (MCF7) more effective than cisplatin. Compared to its effect on cancer cells, compound 13 is much less effective on non-cancer breast cell lines, as its GI 50 values are 9.0 ± 0.1 μM and 12.3 ± 0.1 μM against 184B5 and MCF10A, respectively (Table 1) . Furthermore, data from screening of the NCI-60 cancer panel show that compound 13 is effective on many different human cancers ( Supplementary Fig. S2 ). Together, these data demonstrate that compound 13 has substantial potential as an effective and potentially safe anticancer agent. Therefore, we examined its effects on several cellular and molecular biological aspects to gain a better understanding about its mode of function.
Cancer cells are arrested at prometa-meta phase in the presence of compound 13 due to abnormal mitotic chromosomal arrangement, eventually leading to cell death with sub-G1 DNA content. To gain a better understanding about the molecular mechanism of compound 13 on antigrowth/ cell-killing, HeLa S3 cells synchronized at G1/S by double thymidine treatment (DT) (Fig. 4b) were released into complete medium for 6 h, at which time most cells are at late S-G2/M phase (Fig. 4c) . The cells were then maintained for additional 6 h in the absence (Fig. 4d) or presence of 10 μM compound 13 (Fig. 4e) . More than 62% of cells progressed into G1 of the next cell cycle in the sham control (Fig. 4d) . In contrast, more than 62% of cells were still in G2/M in the presence of compound 13, indicating that the compound causes cell cycle arrest at G2/M (Fig. 4e) . To gain further insights, we examined the active/inactive status of proteins involved in the regulation of the G2-M-G1 transition. Western blot data in Fig. 5a (and Supplementary Fig. S3 for quantitation) show that, unlike in the sham control, both Thr161 and Tyr15 residues on Cdk1 kinase are highly phosphorylated at 2-3 h post-nocodazole in the presence of compound 13. Interestingly, the phosphorylation on Tyr15 was substantially down-regulated at 1 h post-nocodazole, prior to the dramatic increase in phosphorylation at 2-3 h post-nocodazole. Together, these data suggest that cancer cells briefly progressed toward M phase (i.e., 1 h post-nocodazole) even in the presence of compound 13; however, they were then arrested at metaphase due to the inactivation of Cdk1, at the space between Thr161 phosphorylation and Tyr15 dephosphorylation. Cdc25C phosphatase is very active at 2-3 h post-nocodazole in the sham control but almost completely inactive in the presence of compound 13. This indicates that the continuous activation of Cdk1 after 1 h post-nocodazole is blocked in cells treated with compound 13, probably due to the failure of the Cdc25C-mediated Tyr15 dephosphorylation (Fig. 5b) . Similarly, Wee1 is mostly inactive by 3 h post-nocodazole in sham control; however, it is very active in the presence of compound 13. This also suggests that cells try to block further cell cycle progression beyond early M phase by inactivating Cdk1 activity. Since the level of securin is low, cell cycle is likely arrested prior to the chromatin separation stage in the presence of compound 13.
To gain further insight into the cellular mechanism involved in the cell cycle arrest, we examined cell morphology in the context of mitotic progress. We found that overall 44% of mitotic cells contained multiple centrosomes and other abnormalities in mitotic chromosomal arrangement ( Fig. 6a,b ; Supplementary Fig. S4 ). Many of these cells are apparently arrested at the spindle checkpoint stage. Even those cells undergo cell division (probably after prolonged arrest) often segregated with uneven cell sizes (arrows in Fig. 6a ). Together, these data indicate that compound 13 causes the formation of multiple centrosomes, which results in defect in the arrangement of normal mitotic chromosomes, eventually leading to cell death.
Compound 13 causes an increase in lysosome volume. We previously found that CQ causes an increase in lysosomal volume 5 , probably due to the accumulation of protonated CQ in the lysosome 26, 27 . Since the structure of compound 13 contains the main scaffold of CQ, we examined whether cells treated with compound www.nature.com/scientificreports www.nature.com/scientificreports/ 13 also results an increase in the lysosomal volume. As shown in Fig. 7 , the treatment of cells with compound 13 resulted in a substantial increase in lysosomal volume. Interestingly, the MCF10A non-cancer cells treated with compound 13 did not show the same degree of increase in lysosomal volume ( Supplementary Fig. S5 ). This www.nature.com/scientificreports www.nature.com/scientificreports/ different reaction between cancer and non-cancer cells could be, at least in part, why compound 13 is more potent against cancer than non-cancer cells.
Compound 13 kills cancer cells highly effectively when combined with bortezomib (BTZ) or monastrol. Compound 13 at 2.7 μM effectively killed MCF7 cells by 48 h of treatment (Fig. 8a) . Furthermore, compound 13 showed highly synergistic effects when combined with BTZ or monastrol ( Fig. 8b; Supplementary  Fig. S6 ). For example, neither 6 nM BTZ nor 0.75 µM of compound 13 resulted in substantial HeLa cell death by 48 h post-treatment. However, the combination of 6 nM BTZ and 0.75 μM of compound 13 essentially wiped out the entire cell population by 48 h post-treatment, with sub-G1 DNA content typically shown with cells undergoing apoptosis. Similarly, the sequential treatment of monastrol and compound 13 wiped out the entire HeLa cell population within 6 h of the treatment (Supplementary Fig. S6 ).
Conclusion
We here report the examination of thirty-six 4-aminoquinoline derived sulfonyl analogs designed and synthesized by a pharmacophore hybrid approach. Most of the hybrid compounds exhibited improved anticancer activity against human breast cancer cells. We found that compounds 8, 13, 14, 16, 21, 22, 26, 35, 40 and 42 are promising, as they showed stronger antigrowth/antiproliferation activity against cancer cells than non-cancer cells. Among them, 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (13; VR23 28 ) is especially desirable as it is not only the most potent one among this series but also shows preferential growth inhibition/ cell-killing against cancer over non-cancer cells. For example, up to 17.6-fold higher concentration of compound 13 is required to achieve the same GI 50 value against non-cancer cells when compared to cancer cells (0.7 μM for MDA-MB468 vs 12.3 μM for MCF10A in Table 1 ). Furthermore, compound 13 is effective on many different types of cancers ( Supplementary Fig. S2 ).
Our data show that compound 13 causes cell cycle arrest at the prometa-metaphase cell cycle position due to the inactivation of Cdk1 through the down-regulation of Cdc25C activity and upregulation of wee1 (Figs 4, 5 and Supplementary Fig. S3 ), which is likely caused by the formation of multiple centrosomes in response to compound 13 ( Fig. 6; Supplementary Fig. S4 ). As a result, cells eventually die with sub-G1 DNA content typically shown with apoptotic cells ( Fig. 8; Supplementary Fig. S6 ). Compound 13 shows highly synergistic effects when combined with BTZ or monastrol ( Fig. 8b; Supplementary Fig. S6 ).
Like its parental CQ, compound 13 causes an increase in lysomal volume in cancer cells (Fig. 7) . We previously found that CQ-mediated increase in lysosomal volumes makes cells vulnerable to anticancer therapies such as radiation 5, 6 . Since compound 13-mediated increase in lysosomal volumes is more cancer cell specific ( Fig. 7 : Supplementary Fig. S5 ), the differential effects on cancer and non-cancer cells may contribute at least in part to the preferential cancer cell-killing effect by compound 13. Overall, our data presented here demonstrates that www.nature.com/scientificreports www.nature.com/scientificreports/ the hybrid pharmacophore-based approach is very useful in developing effective and potentially safe anticancer agents, and compound 13 possesses a highly desirable property as potential anticancer agent.
Materials and Methods
Melting points (mp) were taken in open capillaries on the Complab melting point apparatus. Elemental analysis was performed on a Perkin-Elmer 2400 C, H, N analyzer and values were within the acceptable limits of the calculated values. The 1 H spectra were recorded on a DPX-500 MHz Bruker FT-NMR spectrometer using CDCl 3 and DMSO-d 6 as solvent. The chemical shifts were reported as parts per million (δ ppm) tetramethylsilane (TMS) as an internal standard. Mass spectra were obtained on a JEOL-SX-102 instrument using electron spray mass spectroscopy (ES-MS). The progress of the reaction was monitored on readymade silica-gel plates (Merck) using chloroform-methanol (9:1) as solvent. Iodine was used as a developing agent or by spraying with the Dragendorff 's reagent. Chromatographic purification was performed over a silica gel (100-200 mesh). All chemicals and reagents obtained from Aldrich (USA) were used without further purification. -4-piperazin-1-yl-quinoline (3-4) . A mixture of 7-substituted-4 -chloro-quinoline (10.10 mmol), piperazine (2.61 g, 30.30 mmol) or propane-1,3-diamine (30.30 mmol) and triethylamine (1.4 mL, 10.10 mmol) were heated slowly to 80 °C > 1 h while stirring. The temperature was then increased to 130-140 °C for 6 h where it was kept while stirring continuously. The reaction mixture was cooled to room temperature and taken up in dichloromethane. The organic layer was washed with 5% aq. NaHCO 3 , followed by washing with water and then with brine. The organic layer was dried over anhydrous Na 2 SO 4 and solvent was removed under reduced pressure, and the residue was then precipitated by addition of mixture of solvent hexane: chloroform (8:2). General synthesis of 7-substituted-4-(4-(alkyl/aryl/heteroalkylsulfonyl)piperazin-1-yl) quinolone (7-24). A solution of compound 7-substituted-4-piperazin-1-yl-quinoline (3.20 mmol) in anhydrous THF (25 mL) under a nitrogen atmosphere was added triethylamine (0.44 mL, 3.20 mmol). The mixture was cooled to below 0 °C. Alkyl/aryl/heteroalkyl sulfonyl chloride (3.20 mmol) was added slowly, keeping the temperature below 5 °C, and the reaction was stirred in an ice bath 1 h. After dilution with saturated NaHCO 3 solution (20 mL), the reaction was extracted with ether (2X). The organic extracts were dried over Na 2 SO 4 , filtered and evaporated to leave crude compound. The crude product was purified through chromatographed on silica gel, eluting with chloroform/methanol (10/0 to 9/1).
General synthesis of 7-substituted

7-Chloro-4-piperazin-1-yl-quinoline (3).
4-Piperazin-1-yl-7-trifluoromethyl-quinoline (4).
7-Chloro-4-(4-(methylsulfonyl)piperazin-1-yl)quinoline (7)
. White solid; 72% yield; IR (KBr, cm www.nature.com/scientificreports www.nature.com/scientificreports/ -4-(4-tosylpiperazin-1-yl)quinoline (8) . Pale -4-sulfonyl)-piperazin-1-yl]-7-trifluoromethyl-quinoline (17) . Creamy 
7-Chloro
yellowish white solid; 66% yield; mp 190-192 °C; IR (KBr, cm −1 ): 1168.7 (SO 2 ); 1 H NMR (500 MHz, CDCl 3 ): δ 2.51 (s, 3 H, CH 3 ), 3.37 (s, 8 H, N
7-Chloro-4-(4-(biphenylsulfonyl)piperazin-1-yl)quinoline (9).
7-Chloro-4-(4-(4-chlorophenylsulfonyl)piperazin-1-yl)quinoline (10
7-Chloro-4-(4-(2,4-dichlorophenylsulfonyl)piperazin-1-yl)quinoline (11
7-Chloro-4-(4-(3-nitrophenylsulfonyl)piperazin-1-yl)quinoline (12)
.
7-Chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (13)
5-(4-(7-Chloroquinolin-4-yl)piperazin-1-ylsulfonyl)-N,N-dimethylnaphthalen-1-amine (14)
4-(4-Methanesulfonyl-piperazin-1-yl)-7-trifluoromethyl-quinoline (16).
4-[4-(Toluene
4-[4-(Biphenyl-4-sulfonyl)-piperazin-1-yl]-7-trifluoromethyl-quinoline (18). White solid; 76%
yield; mp 148-150 °C; IR (KBr, cm 2 C), 110.72, 115.38, 119.50, 121.27, 123.25, 124.56, 124.93, 124.98, 127.97, 128.28 -(7-subtituted-quinolin-4-yl)-popane-1,3-diamine (5 or 6) (3.20 mmol) in anhydrous THF (25 mL) under a nitrogen atmosphere triethylamine (0.44 mL, 3.20 mmol) was added. The mixture was cooled to below 0 °C. Alkyl/aryl/heteroalkyl sulfonyl chloride (3.20 mmol) was added slowly, keeping the temperature below 5 °C, and the reaction was stirred in an ice bath 1 h. After dilution with saturated NaHCO 3 solution (20 mL), the reaction was extracted with ether (2X). The organic extracts were dried over Na 2 SO 4 , filtered and evaporated to leave crude compound. The crude product was purified through chromatographed on silica gel, eluting with chloroform/methanol (10/0 to 8/2). -N-[3-(7-trifluoromethyl-quinolin-4-ylamino) Cell lines. The human MDA-MB231, MCF7 and HeLa cell lines were purchased from American Tissue Culture Collection (ATCC) (Manassas, VA), and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine. 184B5 and MCF10A immortalized breast cells (ATCC) were maintained in mammary epithelial basal medium supplemented with an MEGM mammary epithelial singlequot kit (Cambrex). Cells were grown at 37 °C with 5% CO 2 , 95% air under the humidified conditions. Cell line authentication was carried out by Genetica DNA Laboratories (Burlington, NC) using a short tandem repeat (STR) profiling method (March 2015; July 2015; September 2016).
4-[4-(4-Chloro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethyl-quinoline (19)
.www.nature.com/scientificreports www.nature.com/scientificreports/ Ar-H), 8.64-8.65 (d, J = 5.0 Hz, 1 H, Ar-H), 8.82-8.83 (d, J = 5.0 Hz, 1 H, Ar-H); 13 C NMR (125 MHz, CDCl 3 ): δ 45.45 (2 C), 45.51 (2 C), 51.78 (
3-[4-(7-
N-[3-(7-Chloro-quinolin-4-ylamino)-propyl]-methanesulfonamide (25
3-Nitro
Reagents. Chloroquine diphosphate and cisplatin were purchased from Sigma-Aldrich Canada Ltd (Oakaville, ON, Canada). All the compounds were dissolved in 10-20 mM dimethyl sulfoxide (DMSO) and stored at −20 °C until use. The stock solution was diluted in culture medium (0.1-100 μM) immediately before use. The final concentration of DMSO in the SRB-based cytotoxicity assays did not exceed 0.1%. To rule out that the DMSO concentration used may affect cell proliferation, culture medium containing equivalent concentration of DMSO was used as a negative control in all experiments. In all studies, the concentration of DMSO used did not notably show any antiproliferative effect.
www.nature.com/scientificreports www.nature.com/scientificreports/ SRB assay. Antiproliferative/antigrowth effects were determined by a SRB-based protocol 6, 23 . For a typical screening experiment, 5,000-10,000 cells were inoculated into 100 µL medium per well of a 96-well microtiter plate as described previously 8 . Briefly, after the inoculation, the microtiter plate was incubated at 37 °C, 5% CO 2 , 95% air and 100% relative humidity for 24 h, prior to addition of experimental drugs. Some of the sample wells were fixed with 25 µL of 50% tricholoroacetic acid (TCA) as a control of the cell population for each cell line at the time of drug addition (Tz). An aliquot of the frozen stock was thawed and diluted to a desired final maximum test-concentration with complete medium. Two to ten-fold serial dilutions were made to provide a total of seven drug concentrations (and a control [C] ). Following addition of drugs, the culture plate was incubated for additional 48 h. Cells were fixed in situ by slowly adding 25 µL of ice-cold 50% (w/v) TCA (final concentration, 10% TCA), and were then incubated for 60 min at 4 °C. The supernatant was discarded, and the plate was washed five times with tap water, followed by air-dry. 50 µL of SRB solution at 0.4% (w/v) in 1% acetic acid was added to each well, and the plate was incubated for >30 min at room temperature. Unbound SRB was removed by five washes with tap water, followed by air-drying. The cells "stained" with SRB were solubilized with 10 mM trizma base, and the absorbance was read on an automated plate reader at a wavelength of 515-564 nm. The relative growth rate (%) was calculated for each of the compound concentrations according to the following formula:
In the formula, time zero (Tz), control growth (C), and OD for different concentration of tested compounds (Ti). The GI 50 for each compound was obtained from a non-linear Sigmoidal dose-response (variable slope) curve which is fitted by GraphPad Prism v.4.03 software. Values were calculated for each of these parameters if the level of activity was reached. However, if the effect was not reached or was exceeded, the value for that parameter was expressed as greater or less than the maximum or minimum concentration tested.
Flow cytometry. Cells (2.0 × 10 6 ) were harvested by centrifugation at 1,000 rpm on a bench-top centrifuge for 5 min, followed by fixation with ice-cold ethanol (70%) for 30 min to overnight at −20 °C 13 . The ethanol was then removed by centrifugation, and cells were resuspended in 1 × PBS solution, followed by centrifuge. The cell pellet was than stained with propidium iodide (PI) master mix (100 μg/mL RNase A, 100 μg/mL PI, 0.3% Nonidet P-40 and 0.1% sodium citrate in distilled water) for 30 min at 37 °C. DNA content was measured using a Beckmann Coulter Cytomics FC500 (Beckman Coulter, Fullerton, CA), and the proportion of cell populations in G0/G1, S, and G2/M phases of cell cycle was calculated on the basis of DNA distribution histograms using CXP software.
Microscopy and cell staining. All immunocytochemistry experiments were visualized by confocal microscopy using a Zeiss 510 Meta laser scanning microscope (Carl Zeiss) equipped with a 63× objective lens. Three lasers were utilized for excitation with the following band pass filter settings used for detection: Argon 488 nm (band pass 505-530), HeNe 543 nm (long pass 560) and 633 nm (long pass 650). All images were captured and analyzed using LSM 510 software included with the microscope (LSM Image Examiner, Carl Zeiss).
LysoTracker Red sDND-99 staining was carried out as recommended by the manufacturer (Molecular Probes, Eugene, OR). Briefly, cells grown on a cover slip were incubated in 50 nM LysoTracker Red DND-99 in serum-free RPMI-1640 medium for 30 min and then rinsed once with serum-free medium. The cells were washed three times with ice-cold medium, incubated in fresh medium for 45 min at 37 °C, and then washed once with fresh medium. Subsequently, the cells were examined by fluorescence microscopy using two filters (for green and red images) sequentially. Merging the two color images was done using Northern Eclipse software.
Western blot and densitometry were carried out as we described previously 29, 30 .
